Home / Business and Economy / Boston Scientific Buys Penumbra for $14.5B
Boston Scientific Buys Penumbra for $14.5B
15 Jan
Summary
- Boston Scientific is acquiring Penumbra for approximately $14.5 billion.
- The deal offers Penumbra shareholders $374 per share.
- The acquisition is anticipated to finalize in 2026.
Boston Scientific has agreed to acquire medical device company Penumbra in a substantial deal worth around $14.5 billion. This strategic acquisition is designed to significantly enhance Boston Scientific's existing vascular product portfolio, bringing new innovations and capabilities to the market.
The terms of the agreement value Penumbra at $374 per share, which represents a premium of approximately 19.3% over its recent closing stock price. This move reflects a significant investment by Boston Scientific to expand its market presence and technological reach in the critical vascular sector.
This significant transaction is expected to be finalized in 2026, marking a new chapter for both companies. While Penumbra's shares saw a notable increase in premarket trading following the announcement, Boston Scientific's stock experienced a slight decline.
